Ticker brief
ARWR ARROWHEAD PHARMACEUTICALS IN
Consumer, Non-cyclical · Biotechnology
last close
$58.02
1 day
-0.6%
14 days
-7.5%
mkt cap
·
signals 14d
25
authors 14d
14
crowd 14d
+1.2σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-16 · now +0.55 (−1 bearish … +1 bullish)
Who spoke14
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @harry03994688 | A | -0.16 | 7 | +0.31 |
| @BioStocks | C | -1.77 | 3 | +0.45 |
| @Biotech2k1 | A | +1.11 | 3 | +0.53 |
| @BiopharmIQ | B | · | 2 | -0.05 |
| @StockPatternPro | C | -0.75 | 1 | +0.70 |
| @OzmosiHealth | C | · | 1 | +0.40 |
| @Briefingcom | B | -2.26 | 1 | +0.20 |
| @OpenOutcrier | C | · | 1 | +0.55 |
| @BruceTennen | C | -1.45 | 1 | +0.15 |
| @newsinvesting | C | · | 1 | +0.60 |
| @UTEX_io | C | +0.04 | 1 | +0.40 |
| @PrismMarketView | C | · | 1 | +0.50 |
| @alexkoh | B | -1.37 | 1 | +0.25 |
| @BiotechCH | B | +1.42 | 1 | +0.55 |
Recent signals25of 25 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiotechCH | +0.55 | Early clinical data suggest ARWR successfully delivered an siRNA antibody conjugate. | +3.8% | tweet ↗ |
| 2026-10-16 | @Biotech2k1 | +0.55 | The author identifies high-quality biotech names trading at substantial discounts from their highs. | +3.8% | tweet ↗ |
| 2026-10-15 | @Biotech2k1 | +0.50 | Identifies a basket of biotech names viewed as mispriced excellence. | -0.8% | tweet ↗ |
| 2026-10-15 | @BioStocks | +0.40 | UBS assumed coverage of ARWR with a Buy rating and $109 target. | -0.8% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.05 | Favors ALNY's focus on unmet, less-contested indications while noting ARWR's first drug overlaps Ionis. | -0.6% | tweet ↗ |
| 2026-10-14 | @Biotech2k1 | +0.55 | Calls ARWR high quality and attractively valued while discussing alternative biotech selections. | -0.6% | tweet ↗ |
| 2026-10-14 | @BiopharmIQ | -0.10 | Lists opening price moves and biotech news catalysts; output is capped at the first six tickers. | -0.6% | tweet ↗ |
| 2026-10-14 | @alexkoh | +0.25 | Reports Arrowhead Pharmaceuticals up 3.17% intraday. | -0.6% | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.50 | Interim tau-lowering results are compared with three competing programs. | -0.6% | tweet ↗ |
| 2026-10-14 | @UTEX_io | +0.40 | Multi-company event roundup led by a favorable settlement and other discrete catalysts. | -0.6% | tweet ↗ |
| 2026-10-14 | @newsinvesting | +0.60 | Early ARO-MAPT data show substantial tau-protein reductions. | -0.6% | tweet ↗ |
| 2026-10-14 | @BruceTennen | +0.15 | Lists three long-side watches alongside hotter inflation and a Treasury-yield jump. | -0.6% | tweet ↗ |
| 2026-10-14 | @OpenOutcrier | +0.55 | Arrowhead's drug reduced tau levels by 73% in early trial data. | -0.6% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.70 | Calls siRNA a large market and praises Arrowhead's technology | -0.6% | tweet ↗ |
| 2026-10-14 | @Briefingcom | +0.20 | Lists leading premarket gaps; ticker cap retains the five gainers and largest decliner. | -0.6% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.55 | Expects Alnylam to lead ALK7 while viewing obesity as large enough for both firms | -0.2% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.15 | Believes Alnylam can commercialize ALN-2232 itself, while noting uncertainty | -0.2% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.50 | Extensive ALK7 obesity thesis concludes ALNY reaching a $1T valuation is unavoidable | -0.2% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.50 | Views obesity as a lucrative market supporting self-commercialization by both firms | -0.2% | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.00 | Summarizes midday biotech news and associated stock moves for a broad list. | -5.6% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.40 | Reports Arrowhead's entry into the FDA STAR pilot program for plozasiran. | -5.6% | tweet ↗ |
| 2026-10-07 | @BioStocks | +0.45 | Explains that STAR entry provides a six-month priority review and preserves Arrowhead's voucher. | -5.6% | tweet ↗ |
| 2026-10-07 | @BioStocks | +0.50 | FDA granted plozasiran entry into the STAR Pilot Program for severe hypertriglyceridemia. | -5.6% | tweet ↗ |
| 2026-10-04 | @StockPatternPro | +0.70 | Trade ARWR long for a $20-$30 bounce, with a tight stop at 56. — Provides an explicit tactical trade, expected bounce magnitude, and stop. | -9.6% | tweet ↗ |
| 2026-10-04 | @harry03994688 | -0.30 | Explains a clear investment preference for ALNY over ARWR based on efficacy, culture, and R&D strategy. | -9.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.